Crossref
PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay
Clinical Ovarian Cancer · 2011
DOI: 10.1016/j.cloc.2012.02.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Ovarian Cancer, 2011. Verfasst von J. Tate Thigpen. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Thigpen, J. T. (2011). PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay. Clinical Ovarian Cancer. https://doi.org/10.1016/j.cloc.2012.02.002
Vancouver
Thigpen JT. PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay. Clinical Ovarian Cancer. 2011. doi:10.1016/j.cloc.2012.02.002
BibTeX
@article{Thigpen2011,
author = {Thigpen, J. Tate},
title = {PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay},
journal = {Clinical Ovarian Cancer},
year = {2011},
doi = {10.1016/j.cloc.2012.02.002}
}
EUVIMED